# Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

> **NCT07348484** · — · NOT_YET_RECRUITING · sponsor: **Instituto de Investigación Biomédica de Salamanca** · enrollment: 300 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT07348484
- **Lead sponsor:** Instituto de Investigación Biomédica de Salamanca
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348484, "Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07348484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*